A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Bridgewater Associates, LP holds 3,366 shares of BMRN stock, worth $252,685. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,366
Previous 190,970 98.24%
Holding current value
$252,685
Previous $18.4 Million 98.41%
% of portfolio
0.0%
Previous 0.1%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$83.81 - $99.0 $15.7 Million - $18.6 Million
-187,604 Reduced 98.24%
3,366 $293,000
Q4 2023

Feb 14, 2024

BUY
$76.22 - $98.51 $2.25 Million - $2.91 Million
29,576 Added 18.33%
190,970 $18.4 Million
Q3 2023

Nov 13, 2023

BUY
$85.07 - $94.48 $971,329 - $1.08 Million
11,418 Added 7.61%
161,394 $14.3 Million
Q2 2023

Aug 11, 2023

BUY
$86.68 - $100.3 $2.25 Million - $2.6 Million
25,932 Added 20.91%
149,976 $13 Million
Q1 2023

May 12, 2023

BUY
$87.74 - $117.27 $1.55 Million - $2.07 Million
17,665 Added 16.61%
124,044 $12.1 Million
Q4 2022

Feb 13, 2023

SELL
$80.93 - $108.63 $94,283 - $126,553
-1,165 Reduced 1.08%
106,379 $11 Million
Q3 2022

Nov 10, 2022

BUY
$82.16 - $96.94 $5.57 Million - $6.58 Million
67,829 Added 170.79%
107,544 $9.12 Million
Q2 2022

Aug 11, 2022

BUY
$71.48 - $86.85 $1.43 Million - $1.74 Million
20,065 Added 102.11%
39,715 $3.29 Million
Q1 2022

May 13, 2022

BUY
$74.28 - $92.69 $420,944 - $525,274
5,667 Added 40.53%
19,650 $1.52 Million
Q4 2021

Feb 14, 2022

SELL
$71.72 - $91.47 $1,936 - $2,469
-27 Reduced 0.19%
13,983 $1.24 Million
Q3 2021

Nov 12, 2021

SELL
$74.77 - $85.47 $685,715 - $783,845
-9,171 Reduced 39.56%
14,010 $1.08 Million
Q2 2021

Aug 13, 2021

BUY
$75.51 - $84.79 $735,693 - $826,108
9,743 Added 72.5%
23,181 $1.93 Million
Q1 2021

May 14, 2021

BUY
$74.73 - $90.69 $1 Million - $1.22 Million
13,438 New
13,438 $1.02 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $13.9B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track Ray Dalio's Portfolio

Track Ray Dalio Portfolio

Follow Ray Dalio (Bridgewater Associates, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.